Why switch from warfarin to NOACs?

@article{Verdecchia2016WhySF,
  title={Why switch from warfarin to NOACs?},
  author={Paolo Verdecchia and Fabio Angeli and Adolfo Aita and Claudia Bartolini and Gianpaolo Reboldi},
  journal={Internal and Emergency Medicine},
  year={2016},
  volume={11},
  pages={289-293}
}
Several patients with non-valvular atrial fibrillation treated with warfarin or other vitamin-K antagonists (VKA) might benefit from switching to an oral non vitamin-K antagonist anticoagulant (NOAC). In the absence of randomised comparative trials of switching to NOACs versus maintaining VKA treatment, several considerations argue in favour of a switching strategy. First, there is conclusive evidence that haemorrhagic strokes and intracranial bleedings are much fewer in number with NOACs than… 
Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
TLDR
Changing trends in treatment with anticoagulants for patients with non-valvular atrial fibrillation observed within less than two years provide important information to healthcare services to estimate future pharmaco-economic costs for such treatments.
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy
TLDR
Identifying and managing potential PK drug interactions with NOACs remains a priority to optimise clinical benefit of these anticoagulant therapy with management remaining clinically challenging.
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
TLDR
Evidence thus far indicates that rivaroxaban is superior to warfarin and similar to dabigatran, apixaban and edoxaban for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, although rivroxaban may be associated with an elevated bleeding risk compared with other DOACs.
Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation
TLDR
In patients with known AF at high risk for stroke, hospitalization was associated with an increase in OAC uptake, driven mainly by NOAC initiation.
Healthcare Resource Utilization among Non-Valvular Atrial Fibrillation Patients Who Switched from Warfarin to a Novel Oral Anti-Coagulant
TLDR
Switching to dabigatran after warfarin discontinuation may lower HCRU among NVAF patients compared with switching to rivaroxaban or apixaban, and post-discharge 30-day readmission rates were comparable among warfar in-to-NOAC switching groups.
Increasing Use of Anticoagulants in Germany and Its Impact on Hospitalization for Intracranial Bleeding
TLDR
Nationwide time trends of prescribed anticoagulants in outpatients and its association to ICB in Germany from 2005 to 2014 are analyzed.
Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation - a prospective cohort study.
TLDR
After regulatory approval, the use ofNOACs in Switzerland steadily increased to about 30% in 2015, whereas switches from VKAs to NOACs were infrequent, suggesting significant guideline-concordant improvements in oral anticoagulation use among patients with atrial fibrillation.
A Literature Review of Antithrombotic Therapy for Patients of Venous Thromboembolic Events with Comorbidity of Coronary Heart Disease.
TLDR
The appropriate antithrombotic therapy when balancing the effectiveness and the risk in different circumstance of concurrence of VTE and CHD is discussed, such as combining anticoagulation therapy, dual antiplatelet therapy (DAPT), triple antithROMbotic Therapy (TAT), thrombolytic therapy and extending therapy, in order to provide safe, standard and effective therapeutic schemes for the clinical management of these patients.
...
...

References

SHOWING 1-10 OF 22 REFERENCES
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
TLDR
Dose adjustment in ROCKET-AF yielded results consistent with the overall trial in comparison with dose-adjusted warfarin, and there was no evidence of heterogeneity in treatment effect across dosing groups.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
TLDR
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Edoxaban versus warfarin in patients with atrial fibrillation.
TLDR
Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.
Dabigatran versus warfarin in patients with atrial fibrillation.
TLDR
Dabigatran appeared to be more efficacious in patients who weighed less and in patients with impaired renal function (in whom the drug ac­ cumulates), pointing to significant interpatient variability in response.
Perioperative management of patients who are receiving a novel oral anticoagulant
TLDR
The current evidence of perioperative thromboembolic and bleeding risk during anticoagulant interruption is derived predominantly from patients receiving VKA therapy, and early studies involving NOACs which mainly focus on patients who are receiving dabigatran.
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
TLDR
The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control.
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
TLDR
An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented.
Net Clinical Benefit of Oral Anticoagulants: A Multiple Criteria Decision Analysis
TLDR
The results suggest that new oral anticoagulants might be preferred over warfarin, and selecting appropriate medicines according to the patient’s condition based on information from an integrated benefit-risk assessment of treatment options is crucial to achieve optimal clinical outcomes.
...
...